Copyright
©The Author(s) 2020.
World J Clin Cases. Mar 26, 2020; 8(6): 1065-1073
Published online Mar 26, 2020. doi: 10.12998/wjcc.v8.i6.1065
Published online Mar 26, 2020. doi: 10.12998/wjcc.v8.i6.1065
Table 3 Adverse events during treatment with ruxolitinib, n (%)
| Parameter | aGVHD, n = 10 | cGVHD, n = 28 |
| Activation of cytomegalovirus | 3 (30.0) | 0 (0) |
| Activation of Epstein-Barr virus | 1 (10.0) | 4 (14.3) |
| Infection with herpes-zoster virus | 0 (0) | 2 (7.1) |
| Relapse of malignant blood disease | 1 (10.0) | 3 (10.7) |
- Citation: Dang SH, Liu Q, Xie R, Shen N, Zhou S, Shi W, Liu W, Zou P, You Y, Zhong ZD. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. World J Clin Cases 2020; 8(6): 1065-1073
- URL: https://www.wjgnet.com/2307-8960/full/v8/i6/1065.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i6.1065